Author

Peyton C. High

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Advances in Bispecific Antibodies and Antibody–Drug Conjugates for Colorectal Cancer Treatment

BSAbs and bsADCs provide opportunities to improve tumor selectivity, enhance internalization, overcome antigen escape, and expand the population of CRC patients eligible for targeted therapy, as well as discussing the major challenges facing clinical translation.

Maya G. Cappellino, Sean P. Sullivan, Peyton C. High et al. · Antibodies · 0 citations

Open access Aug 2026

Antibody-drug conjugate combination therapy targeting LGR5 and MET with different payloads enhances efficacy in preclinical colorectal cancer models

Findings reveal a reciprocal regulation between MET and LGR5 in response to LGR5- or MET-targeting ADCs in CRC models and support a LGR5/MET dual-targeting therapeutic strategy to enhance efficacy and potentially overcome resistance and relapse.

Shraddha Subramanian, Peyton C. High, Cara Guernsey-Biddle et al. · bioRxiv · 0 citations